8-K: Sanara MedTech Reports Strong 2025 Revenue, Positive 2026 Outlook

Sanara MedTech Inc. announced preliminary Q4 and full-year 2025 financial results with significant revenue growth and introduced optimistic 2026 guidance.

Summary

• Preliminary net revenue for Q4 2025 is expected to be in the range of $27.2 million to $27.7 million, an increase of approximately 3% to 5% compared to Q4 2024.
• Excluding $1.8 million of BIASURGE sales in Q4 2024 due to supply chain issues, Q4 2025 net revenue is expected to increase approximately 11% to 13% year-over-year.
• Preliminary net revenue for the full year 2025 is expected to be in the range of $102.7 million to $103.2 million, an increase of approximately 19% compared to $86.7 million for the full year 2024.
• Excluding the aforementioned $1.8 million of BIASURGE sales in Q4 2024, full year 2025 net revenue is expected to increase approximately 21% to 22% year-over-year.
• As of December 31, 2025, cash was approximately $16.6 million, compared to $15.9 million as of December 31, 2024.
• Long-term debt as of December 31, 2025, was $46.0 million, compared to $30.7 million as of December 31, 2024.
• Full year 2026 net revenue is expected to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to the midpoint of the expected net revenue range for full year 2025.
• The BIASURGE product received an Innovative Technology contract from Vizient, Inc., effective January 1, 2026, expanding access to Vizient's network of healthcare facility customers.
• Plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. commercial market in Q1 2027, following anticipated FDA clearance, targeting peri-articular fractures.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong preliminary revenue growth, optimistic future guidance, and a significant contract win with Vizient. Progress on a new product pipeline (OsStic) also contributes positively. However, the substantial increase in long-term debt and the preliminary nature of the financial results introduce a degree of caution.

Positives

• Strong preliminary net revenue growth for full year 2025 of approximately 19% (21-22% adjusted for prior year anomaly).
• Solid preliminary net revenue growth for Q4 2025 of approximately 3-5% (11-13% adjusted for prior year anomaly).
• Positive financial guidance for full year 2026, projecting 13% to 17% net revenue growth.
• Secured an Innovative Technology contract with Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, for BIASURGE, significantly expanding market access.
• Progress in the strategic alliance with Biomimetic Innovations Ltd (BMI) and the development of OsStic, a new product targeting peri-articular fractures.
• Increased cash balance to $16.6 million as of December 31, 2025, from $15.9 million in the prior year.
• Strategic focus on becoming a 'pure play surgical business' for sustainable, long-term growth and profitability in the multi-billion-dollar surgical solutions market.

Negatives

• Long-term debt increased significantly to $46.0 million as of December 31, 2025, from $30.7 million as of December 31, 2024.
• The financial results reported are preliminary and unaudited, subject to change upon completion of audit procedures.

Risks

• Preliminary financial information is subject to changes and finalization based upon management's ongoing review and completion of all quarter and year-end closing procedures.
• Actual results may differ from estimates due to the completion of the audit and other developments.
• Forward-looking statements involve risks, contingencies, and uncertainties such as the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, and pricing.
• Uncertainties are associated with the development and process for obtaining regulatory approval for new products, such as OsStic.
• Risks related to the ability to consummate and integrate acquisitions.

Future Outlook

The company expects to deliver net revenue growth of approximately 13% to 17% year-over-year in 2026, primarily fueled by sales of its soft tissue products. It aims to be a pure play surgical business for the treatment of surgical wounds, positioning itself for sustainable, long-term growth and profitability by expanding its share of the multi-billion-dollar surgical solutions market. The OsStic Synthetic Injectable Structural Bio-Adhesive is anticipated for U.S. commercial market introduction in Q1 2027, pending FDA clearance.

Management Comments

• "Our team delivered strong performance in 2025, culminating in preliminary net revenue of approximately $103 million, an increase of approximately 19% year-over-year."
• "In the fourth quarter of 2025, our preliminary net revenue increased in the range of 11% to 13% year-over-year, excluding approximately $1.8 million of BIASURGE sales in the prior year period, consistent with the range of expectations shared on our Q3 earnings call."
• "Operationally, we made important progress across multiple areas during the fourth quarter. Importantly, we secured a new contract with Vizient, Inc. – the largest group purchasing organization in the U.S. – which significantly expands access to BIASURGE at contracted pricing and pre-negotiated terms."
• "In addition, we enhanced our sales and distribution network, while also working to expand our product portfolio through our initiatives with BMI related to OsStic."
• "Looking ahead to 2026, we expect to deliver net revenue growth of approximately 13% to 17% year-over-year, fueled primarily by sales of our soft tissue products."
• "We are entering 2026 as a pure play surgical business for the treatment of surgical wounds, which we believe positions Sanara to deliver sustainable, long-term growth and profitability as we expand our share of the multi-billion-dollar surgical solutions market."

Industry Context

The medical technology industry, particularly the surgical market, is highly competitive and driven by innovation and market access. Sanara MedTech's focus on becoming a 'pure play surgical business' aligns with a strategy of specialization to capture a larger share of the multi-billion-dollar surgical solutions market. Securing an Innovative Technology contract with Vizient, a major Group Purchasing Organization (GPO), is a critical step for market penetration, as GPOs significantly influence product adoption and purchasing decisions within healthcare systems. The development of new products like OsStic demonstrates a commitment to addressing unmet clinical needs and expanding the product portfolio, which is essential for sustained growth in this sector.

Comparison to Industry Standards

• The reported preliminary full-year 2025 revenue growth of 19% (21-22% adjusted) and 2026 guidance of 13-17% growth are strong performance indicators, generally exceeding average growth rates for many established medical technology companies.
• The successful acquisition of an Innovative Technology contract from Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, signifies that BIASURGE has been recognized by hospital experts for its unique qualities and potential to improve healthcare, positioning it favorably against competitors in the advanced surgical solution market.
• The planned introduction of OsStic in Q1 2027 targets the significant market of over 100,000 peri-articular fractures annually, indicating a strategic move into a high-demand niche within orthopedic surgery, comparable to other innovative biomaterial companies developing solutions for bone repair and fixation.

Stakeholder Impact

• Shareholders: Potential for increased share value due to strong revenue growth, positive future guidance, and expanded market access. However, the increase in long-term debt could be a point of concern.
• Employees: Continued growth and product development initiatives suggest job stability and potential for expansion within the company.
• Customers (Healthcare Facilities): Enhanced access to BIASURGE through the Vizient contract at pre-negotiated terms, potentially leading to cost efficiencies and improved product availability. Anticipated new product (OsStic) offers future treatment options.
• Suppliers: Increased demand for products like BIASURGE and future products like OsStic could lead to increased business for suppliers.
• Creditors: The significant increase in long-term debt implies higher exposure, but the strong revenue growth and positive outlook may provide comfort regarding repayment capacity.

Next Steps

• Completion of the independent registered public accounting firm's procedures and audit of financial statements for the year ended December 31, 2025.
• Finalization of financial results for the fourth quarter and fiscal year 2025.
• Continued sales and distribution of soft tissue products to drive 2026 revenue growth.
• Anticipated clearance by the U.S. Food and Drug Administration for OsStic Synthetic Injectable Structural Bio-Adhesive.
• Introduction of OsStic to the U.S. commercial market in the first quarter of 2027.
• Expansion of market share in the multi-billion-dollar surgical solutions market.

Key Dates

Recommendation

The company demonstrates strong preliminary revenue growth for 2025 and provides robust guidance for 2026, indicating continued momentum in the surgical market. The securing of an Innovative Technology contract with Vizient, the largest GPO, is a significant catalyst for expanding market access and sales for BIASURGE. Progress on the OsStic pipeline also points to future growth opportunities. While the increase in long-term debt is notable, the overall operational and financial trajectory, coupled with strategic market positioning as a 'pure play surgical business,' suggests a positive investment outlook.

Keywords

Sanara MedTech, SMTI, medical technology, surgical market, wound care, BIASURGE, OsStic, Vizient, financial results, revenue guidance, preliminary results, Q4 2025, FY 2025, FY 2026, debt, cash, FDA, strategic alliance